

What is claimed is:

1. Oligodeoxynucleotides for stimulating an adjuvant or treating immune-related diseases, presented in General Formula:

5 [General Formula]: HKCGTTCRTGTCSGM (SEQ ID NO: 1)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; and M represents C or A.

2. The oligodeoxynucleotides for stimulating an adjuvant or treating
10 immune-related diseases according to the claim 1,

wherein the oligonucleotides further comprise five nucleotides, presented in following General Formula, at a 5'-terminal end and a 3'-terminal end:

[General Formula]: DKMHKCGTTCRTGTCSGMYK (SEQ ID NO: 2)

15 wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; D represents A, G or T; M represents C or A; M represents C or A; and Y represents C or T.

3. The oligodeoxynucleotides according to any of the claims 1 and 2,
wherein the oligodeoxynucleotides protect normal immune cells when the
20 radiotherapy is applied.

4. The oligodeoxynucleotides according to any of the claims 1 and 2,
wherein the oligodeoxynucleotides treat or prevent skin diseases.

5. The oligodeoxynucleotides according to any of the claims 1 and 2,
wherein the oligodeoxynucleotides maintain balances of various Th1/Th2
immune reactions.

5

6. The oligodeoxynucleotides according to any of the claims 1 and 2,
wherein the oligodeoxynucleotides have a phosphodiester bond or
phosphorothioate bond between the nucleotides.

10

7. The oligodeoxynucleotides according to any of the claims 1 and 2,

wherein the oligonucleotides are selected from the group consisting of

	5'-AGCAGCGTTCGTGTCGGCCT-3'	(SEQ	ID	NO:	3),
	5'-AGCAGCGTTCGTGTGCGCCT-3'	(SEQ	ID	NO:	4),
	5'-AGCAGCGTTCATGTCGGCCT-3'	(SEQ	ID	NO:	5),
15	5'-AGCAGCGTTCGTGTCCGCCT-3'	(SEQ	ID	NO:	6),
	5'-GTATTCGTTCGTGTCGTCCT-3'	(SEQ	ID	NO:	7) and
	5'-TGACTCGTTCGTGTCGCATG-3' (SEQ ID NO: 8).				